Corcept director exercises options, shifts shares
Corcept Therapeutics director James N. Wilson reported several equity moves involving stock options and trust-related holdings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Corcept Therapeutics director James N. Wilson reported several equity moves involving stock options and trust-related holdings. He exercised stock options for 100,000 shares of common stock at an exercise price of $3.88 per share through a derivative conversion.
Of the resulting shares, 10,636 shares of common stock were disposed of to cover the exercise price or tax liability at a price of $36.48 per share in a tax-withholding transaction. He then made a bona fide gift of 89,364 shares of common stock, transferring them without consideration to the James N. Wilson and Pamela D. Wilson Trust.
The filing shows 1,134,532 shares of common stock held indirectly by the James N. Wilson and Pamela D. Wilson Trust, 901,067 shares held indirectly by James and Pamela Wilson Family Partners, and 200,000 shares each held indirectly by the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust. Wilson has voting power over the trust and partnership shares pursuant to voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock option (right to buy) | 100,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 100,000 | $3.88 | $388K |
| Exercise Price or Tax Liability | Common Stock | 10,636 | $36.48 | $388K |
| Gift | Common Stock | 89,364 | $0.00 | $0.00 |
| Other | Common Stock | 89,364 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (4)
- F1. These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options. The options subject to the net exercise were to expire on February 26, 2026.
- F2. Transfer of shares without consideration to the James N. Wilson and Pamela D. Wilson Trust.
- F3. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust and James and Pamela Wilson Family Partners pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
- F4. Fully exercisable.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Corcept (CORT) director James N. Wilson report in this Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.